PI-103 Hydrochloride
(Synonyms: PI 103 hydrochloride;PI103 hydrochloride) 目录号 : GC16379
PI-103 Hydrochloride是一种有效的细胞渗透性多靶点抑制剂，主要作用于PI3K和mTOR信号通路。
Cas No.:371935-79-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
PI-103 Hydrochloride is a potent cell-permeable multi-target inhibitor that primarily acts on the PI3K and mTOR signaling pathways[1]. PI-103 Hydrochloride inhibits PI3K subtypes p110α (8nM), p110β (88nM), p110δ (48nM), and p110γ (158nM), as well as mTOR complexes mTORC1 (20nM) and mTORC2 (83nM), while simultaneously inhibiting DNA-PK activity (2nM)[2]. PI-103 Hydrochloride can induce mitochondrial apoptosis and autophagy in cells[3]. PI-103 Hydrochloride can restore the sensitivity of cancer cells to radiotherapy and chemotherapy[4].
In vitro, pretreatment of Dalton's lymphoma ascites (DLA) cells with PI-103 Hydrochloride (10μM) for 24 hours, followed by stimulation with H₂O₂ (1mM) for 30 minutes, significantly inhibited the PI3K-AKT signaling pathway and induced apoptosis, while reducing the accumulation of reactive oxygen species (ROS)[5]. Pretreatment of Huh7 hepatocellular carcinoma cells with PI-103 Hydrochloride (2μM) for 1 hour, followed by stimulation with EGF (2.5nM) for 15 minutes, significantly inhibited the phosphorylation of key proteins in the PI3K/AKT/mTOR signaling pathway and blocked EGF-stimulated cell proliferation[6].
In vivo, intraperitoneal injection of PI-103 Hydrochloride (10mg/kg) combined with olaparib (10mg/kg) three times per week, used to treat mouse models implanted with MDA-MB-435S cells for 2 weeks followed by radiotherapy (3Gy per fraction), significantly enhanced the inhibitory effect of radiotherapy on triple-negative breast cancer xenografts[7]. Daily intraperitoneal injection of PI-103 Hydrochloride (10mg/kg or 70mg/kg) in FVB/N mice for 8 days to several weeks significantly promoted the growth of melanoma xenografts, while inhibiting thymocyte count and inducing immunosuppression[8].
References:
[1] Park S, Chapuis N, Bardet V, et al. PI-103 Hydrochloride, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia. 2008 Sep;22(9):1698-706.
[2] Raynaud FI, Eccles SA, Patel S, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 Hydrochloride through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009 Jul;8(7):1725-38.
[3] Djuzenova CS, Fischer T, Katzer A, et al. Opposite effects of the triple target (DNA-PK/PI3K/mTOR) inhibitor PI-103 Hydrochloride on the radiation sensitivity of glioblastoma cell lines proficient and deficient in DNA-PKcs. BMC Cancer. 2021 Nov 11;21(1):1201.
[4] Toulany M, Iida M, Keinath S, et al. Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer. Oncotarget. 2016 Jul 12;7(28):43746-43761.
[5] Maurya AK, Vinayak M. PI-103 Hydrochloride attenuates PI3K-AKT signaling and induces apoptosis in murineT-cell lymphoma. Leuk Lymphoma. 2017 May;58(5):1153-1161.
[6] Gedaly R, Angulo P, Hundley J, et al. PI-103 Hydrochloride and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res. 2010 Dec;30(12):4951-8.
[7] Jang NY, Kim DH, Cho BJ, et al. Radiosensitization with combined use of olaparib and PI-103 Hydrochloride in triple-negative breast cancer. BMC Cancer. 2015 Mar 3;15:89.
[8] López-Fauqued M, Gil R, Grueso J, et al. The dual PI3K/mTOR inhibitor PI-103 Hydrochloride promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. Int J Cancer. 2010 Apr 1;126(7):1549-61.
PI-103 Hydrochloride是一种有效的细胞渗透性多靶点抑制剂，主要作用于PI3K和mTOR信号通路[1]。PI-103 Hydrochloride可抑制PI3K亚型p110α（8nM）、p110β（88nM）、p110δ（48nM）和p110γ（158nM），以及mTOR复合物mTORC1（20nM）和mTORC2（83nM），并同时抑制DNA-PK的活性（2nM）[2]。PI-103 Hydrochloride可诱导细胞线粒体凋亡和细胞自噬[3]。PI-103 Hydrochloride可恢复癌细胞的放化疗的敏感性[4]。
在体外，PI-103 Hydrochloride（10μM）预处理Dalton's淋巴瘤腹水（DLA）细胞24小时，随后以H₂O₂（1mM）刺激30分钟，PI-103 Hydrochloride显著抑制PI3K-AKT信号通路并诱导细胞凋亡，同时降低活性氧（ROS）积累[5]。PI-103 Hydrochloride（2μM）预处理Huh7肝癌细胞1小时，随后以EGF（2.5nM）刺激15分钟，PI-103 Hydrochloride显著抑制PI3K/AKT/mTOR信号通路中关键蛋白的磷酸化，同时阻断EGF刺激的细胞增殖[6]。
在体内，PI-103 Hydrochloride（10mg/kg）联合奥拉帕尼（10mg/kg）每周三次腹腔注射，用于处理植入MDA-MB-435S细胞的小鼠模型，持续2周后联合3Gy/次放疗。PI-103 Hydrochloride显著增强了放疗对三阴性乳腺癌异种移植瘤的抑制效果[7]。PI-103 Hydrochloride（10mg/kg或70mg/kg）每日腹腔注射，用于处理FVB/N小鼠，持续8天至数周。PI-103 Hydrochloride显著促进了小鼠体内黑色素瘤移植瘤的生长，同时抑制胸腺细胞数量并诱导免疫抑制[8]。
| Cell experiment [1]: | |
Cell lines | Huh7 cells (human hepatocellular carcinoma cell line) |
Preparation Method | Huh7 cells were maintained in Dulbecco's minimal essential medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) at 37°C, 5% CO₂. Cells were treated with PI-103 Hydrochloride (2μM) at specified concentrations for designated time periods prior to epidermal growth factor (EGF; 2.5μM) stimulation or irradiation. |
Reaction Conditions | 2μM; 1h pretreatment |
Applications | PI-103 Hydrochloride significantly inhibited EGF-stimulated phosphorylation of mTOR (Ser2448, 45% inhibition), S6K (Thr389, 87% inhibition), and AKT (Ser473, 88% inhibition), indicating potent dual inhibition of both mTORC1 and mTORC2 activity. |
| Animal experiment [2]: | |
Animal models | Nude mice |
Preparation Method | Mice were implanted subcutaneously with MDA-MB-435S cells transfected with pGL4 luciferase reporter vector. One week after implantation, mice were treated with intraperitoneal administration of PI-103 Hydrochloride (10mg/kg) alone or in combination with Olaparib (10mg/kg) three times weekly for 2 weeks, followed by irradiation (3Gy per fraction, three times weekly). Mice were observed for 2 weeks post-treatment and analyzed via bioluminescence imaging. |
Dosage form | 10mg/kg; i.p. |
Applications | Combined treatment with PI-103 Hydrochloride and Olaparib significantly reduced tumor volume compared to radiation alone, demonstrating enhanced radiosensitization in triple-negative breast cancer xenografts. PI-103 Hydrochloride alone showed synergistic effects with Olaparib in blocking tumor growth post-irradiation. |
References: | |
| Cas No. | 371935-79-4 | SDF | |
| 别名 | PI 103 hydrochloride;PI103 hydrochloride | ||
| 化学名 | 3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenol;hydrochloride | ||
| Canonical SMILES | C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)O.Cl | ||
| 分子式 | C19H17ClN4O3 | 分子量 | 384.82 |
| 溶解度 | ≥ 19.25 mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5986 mL | 12.9931 mL | 25.9862 mL |
| 5 mM | 519.7 μL | 2.5986 mL | 5.1972 mL |
| 10 mM | 259.9 μL | 1.2993 mL | 2.5986 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet